SCHEMBL23930269

SCHEMBL23930269

COC(=O)c1cc2ccc(N3CCOC3=O)cc2c(=O)n1C(=O)OC(C)(C)C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP12 P39900 3/20 0.37
MMP13 P45452 3/20 0.37
ADAMTS4 O75173 1/20 0.37
MMP1 P03956 1/20 0.37
MMP2 P08253 1/20 0.37
MMP3 P08254 1/20 0.37
MMP7 P09237 1/20 0.37
MMP9 P14780 1/20 0.37
MMP8 P22894 1/20 0.37
MMP14 P50281 1/20 0.37
ADAM17 P78536 1/20 0.37
ADAMTS5 Q9UNA0 1/20 0.37
CCNC P24863 2/20 0.37
CDK8 P49336 2/20 0.37
NR1H2 P55055 1/20 0.37
ELOVL6 Q9H5J4 1/20 0.33
LRRK2 Q5S007 2/20 0.32
CMA1 P23946 2/20 0.32
KDM1A O60341 4/20 0.32
MAOA P21397 4/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30023391 1.00 MMP12 (0.37) MMP12MMP13ADAMTS4MMP1MMP2
SCHEMBL30023854 0.90 MMP12 (0.38) MMP12MMP13ADAMTS4MMP1MMP2
SCHEMBL19964584 0.78 USP30 (0.40) NR1H2USP30CCNB2CDK1CCNB1
SCHEMBL30853473 0.76 ALDH1A1 (0.49) NR1H2
SCHEMBL1201914 0.76 ALDH1A1 (0.49) NR1H2
SCHEMBL23930145 0.74 CCNC (0.42) MMP12MMP13ADAMTS4MMP1MMP2
SCHEMBL30023386 0.74 CCNC (0.42) MMP12MMP13ADAMTS4MMP1MMP2
SCHEMBL23930218 0.74 TBK1 (0.36) NR1H2
SCHEMBL30023425 0.74 TBK1 (0.36) NR1H2
SCHEMBL23930137 0.73 TNKS (0.43) MMP12MMP13ADAMTS4MMP1MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115397822-B CBP/EP300 inhibitors and uses thereof 南京药石科技股份有限公司 2024-04-16 CN disclosed
US-20230159497-A1 CBP/EP300 INHIBITOR AND USE THEREOF PHARMABLOCK SCIENCES (NANJING) , INC. (CN) 2023-05-25 US disclosed
CN-115397822-A CBP/EP300 inhibitors and uses thereof 南京药石科技股份有限公司 2022-11-25 CN disclosed
WO-2021213521-A1 CBP/EP300 INHIBITOR AND USE THEREOF 南京药石科技股份有限公司 (CN) 2021-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159497-A1 CBP/EP300 INHIBITOR AND USE THEREOF EP300, CREBBP, BPTF MMP12 1303/4885MMP13 2333/4885ADAMTS4 4702/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.